億勝生物(01061.HK)參展亞太眼科學會年會報告貝伐珠單抗候選藥物臨牀數據

阿斯達克財經

02/10

億勝生物(01061.HK) 公布，成功參展於2026年2月5日至8日在香港會議展覽中心舉辦的第41屆亞太眼科學會年會(APAO 2026)。公司的海報研究《貝伐珠單抗與雷珠單抗治療溼性年齡相關性黃斑變性的解剖學及患者報告結局：AURA-1研究》獲選大會口頭報告。該報告基於貝伐珠單抗候選藥物(EB12-20145P)的III期臨牀數據，重點闡述了集團在溼性年齡相關性黃斑變性(wAMD)抗血管內皮...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610643573"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610643573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610643573?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230517145836273_s.jpg","is_english":false,"pubTime":"2026-02-10 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610643573","market":"sh","top_or_hot":-1,"title":"億勝生物(01061.HK)參展亞太眼科學會年會 報告貝伐珠單抗候選藥物臨牀數據","media":"阿斯達克財經","content":"<div>\n<p>億勝生物(01061.HK) 公布，成功參展於2026年2月5日至8日在香港會議展覽中心舉辦的第41屆亞太眼科學會年會(APAO 2026)。公司的海報研究《貝伐珠單抗與雷珠單抗治療溼性年齡相關性黃斑變性的解剖學及患者報告結局：AURA-1研究》獲選大會口頭報告。該報告基於貝伐珠單抗候選藥物(EB12-20145P)的III期臨牀數據，重點闡述了集團在溼性年齡相關性黃斑變性(wAMD)抗血管內皮...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>億勝生物(01061.HK)參展亞太眼科學會年會 報告貝伐珠單抗候選藥物臨牀數據</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n億勝生物(01061.HK)參展亞太眼科學會年會 報告貝伐珠單抗候選藥物臨牀數據\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2026-02-10 17:34</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>億勝生物(01061.HK) 公布，成功參展於2026年2月5日至8日在香港會議展覽中心舉辦的第41屆亞太眼科學會年會(APAO 2026)。公司的海報研究《貝伐珠單抗與雷珠單抗治療溼性年齡相關性黃斑變性的解剖學及患者報告結局：AURA-1研究》獲選大會口頭報告。該報告基於貝伐珠單抗候選藥物(EB12-20145P)的III期臨牀數據，重點闡述了集團在溼性年齡相關性黃斑變性(wAMD)抗血管內皮...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN","article_id":"2610643573","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230517145836273_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502413/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610643573","pubTimestamp":1770716040,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"億勝生物(01061.HK) 公布，成功參展於2026年2月5日至8日在香港會議展覽中心舉辦的第41屆亞太眼科學會年會(APAO 2026)。公司的海報研究《貝伐珠單抗與雷珠單抗治療濕性年齡相關性黃斑變性的解剖學及患者報告結局：AURA-1研究》獲選大會口頭報告。該報告基於貝伐珠單抗候選藥物(EB12-20145P)的III期臨床數據，重點闡述了集團在濕性年齡相關性黃斑變性(wAMD)抗血管內皮生長因子(anti-VEGF)療法領域持續取得的臨床進展。(ss/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-02-10 16:25。)AASTOCKS新聞","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","01061":"亿胜生物科技"},"translate_title":"Essex Biologics (01061. HK) participated in the annual meeting of the Asia-Pacific Society of Ophthalmology to report the clinical data of bevacizumab drug candidates","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1.5},"content_text":"億勝生物(01061.HK) 公布，成功參展於2026年2月5日至8日在香港會議展覽中心舉辦的第41屆亞太眼科學會年會(APAO 2026)。公司的海報研究《貝伐珠單抗與雷珠單抗治療濕性年齡相關性黃斑變性的解剖學及患者報告結局：AURA-1研究》獲選大會口頭報告。該報告基於貝伐珠單抗候選藥物(EB12-20145P)的III期臨床數據，重點闡述了集團在濕性年齡相關性黃斑變性(wAMD)抗血管內皮生長因子(anti-VEGF)療法領域持續取得的臨床進展。(ss/a)(港股報價延遲最少十五分鐘。沽空資料截至 2026-02-10 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}

億勝生物(01061.HK)參展亞太眼科學會年會 報告貝伐珠單抗候選藥物臨牀數據

熱議股票

億勝生物(01061.HK)參展亞太眼科學會年會報告貝伐珠單抗候選藥物臨牀數據